Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers

Vaccine

Volumn 19, Issue 15-16, 2001, Pages 2100-2106

  Satti, Iman N ^a   Y Osman, H ^a   Daifalla, N S ^a   Younis, S A ^b   Khalil, E A G ^a   Zijlstra, E E ^a,c   El Hassan, A M ^a   Ghalib, H W ^d  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c UNIVERSITY OF MALAWI   (Malawi)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Immunogenicity; Leishmania major; Safety; Sudan

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; LEISHMANIA MAJOR VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; AUTOCLAVE; BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MALAISE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUDAN; VISCERAL LEISHMANIASIS;

ADULT; ANIMALS; ANTIGENS, PROTOZOAN; BCG VACCINE; DOUBLE-BLIND METHOD; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PROTOZOAN VACCINES; SAFETY; SUDAN; VACCINES, COMBINED;

EID: 0035961560     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00401-1     Document Type: Article

References (30)

1. Control of the leishmaniasis
2. Studies on the leishmaniases in the Sudan: 1. Epidemic cutaneous leishmaniasis in Khartoum
3. Identification of Leishmania from mucosal leishmaniasis by recombinant DNA probes
4. Sudanese mucosal leishmaniasis: Epidemiology, clinical features, diagnosis, immune responses and treatment
5. Experience with vaccines against cutaneous leishmaniasis: Of men and mice
6. Responses to Montenegro antigen after immunization with killed Leishmania promastigotes
7. A field trial of a vaccine against American dermal leishmaniasis
8. Controlled field trial of vaccines against new world cutaneous leishmaniasis
9. Further trials of a vaccine against American cutaneous leishmaniasis
10. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG 1: Skin test reactivity, T-cell proliferation, and interferon-gamma production
11. Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: Antibody responses to mycobacterial and leishmanial antigens
12. A randomized double-blind, controlled trial of killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran
13. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
14. Parasitic diseases
15. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis
16. Vaccine preparation and quality control of killed Leishmania major
17. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Rome (Italy) in cured cutaneous leishmaniasis patients
18. Measurement of delayed type skin-test responses
19. Separation of lymphocytes from blood and bone marrow
20. Cells from healthy non-exposed individuals produce cytokines to selected fractions of Leishmania promastigotes
21. The immunobiology of leishmaniasis
22. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes
23. Effective immunization against cutaneous leishmaniasis with recombinant Calmette-Guerin expressing the Leishmania surface proteinase gp63
24. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis
25. Prevalence of cutaneous leishmaniasis along the Nile River north of Khartoum (Sudan) in the aftermath of an epidemic in 1985
26. T-cell and cytokine responses in leishmaniasis
27. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi
28. IL-12 enhances Th1-T-type response in human Leishmania donovani infections
29. Interleukin-10 production correlates with pathology in human Leishmania donovani infections